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IMMEDIATE COMMUNICATION

Targeting the schizophrenia genome: a fast track strategy from
GWAS to clinic
T Lencz1,2,3 and AK Malhotra1,2,3
The Psychiatric Genomics Consortium–Schizophrenia Workgroup (PGC–SCZ) has recently published a genomewide association
study (GWAS) identifying 4100 genetic loci, encompassing a total of 341 protein-coding genes, attaining genomewide signiﬁcance
for susceptibility to schizophrenia. Given the extremely long time (12–15 years) and expense (4$1 billion) associated with the
development of novel drug targets, repurposing of drugs with known and validated targets may be the most expeditious path
toward deriving clinical utility from these GWAS ﬁndings. In the present study, we examined all genes within loci implicated by the
PGC–SCZ GWAS against databases of targets of both approved and registered pharmaceutical compounds. We identiﬁed 20
potential schizophrenia susceptibility genes that encode proteins that are the targets of approved drugs. Of these, we prioritized
genes/targets that are of clear neuropsychiatric interest and that are also sole members of the linkage disequilibrium block
surrounding a PGC–SCZ GWAS hit. In addition to DRD2, 5 genes meet these criteria: CACNA1C, CACNB2, CACNA1I, GRIN2A and HCN1.
An additional 20 genes coding for proteins that are the targets of drugs in registered clinical trials, but without approved
indications, were also identiﬁed. Although considerable work is still required to fully explicate the biological implications of the
PGC–SCZ GWAS results, pathways related to these known, druggable targets may represent a promising starting point.
Molecular Psychiatry (2015) 20, 820–826; doi:10.1038/mp.2015.28; published online 14 April 2015

INTRODUCTION
After years of effort from hundreds of investigators and tens of
thousands of DNA samples collected worldwide, the Psychiatric
Genomics Consortium–Schizophrenia Workgroup (PGC–SCZ) has
recently published a genomewide association study (GWAS),
which established a list of 4100 genetic loci conveying risk for the
disorder at conventionally accepted standards of statistical signiﬁcance.1 Although representing a watershed event in psychiatric
research, the complexity revealed by the PGC–SCZ results will
require considerable further analysis to yield clinically applicable
insights. GWAS hits, by their nature, involve broad genomic loci
deﬁned by linkage disequilibrium (LD) structure, often containing
multiple genes, and do not provide mechanistic insight without
further experimentation.2 It is noteworthy that relatively few loci
from the PGC–SCZ study implicated speciﬁc amino acid changes
or clearly overlapped gene expression quantitative trait loci, such
that many hundreds of genes were potentially implicated by these
results.
A primary aim of GWAS is to identify potential targets for
pharmaceutical interventions, and the ultimate success of the
PGC–SCZ efforts will be judged, in part, on new treatment
development. Proof of principle for a potential role of GWAS in
target identiﬁcation was established by an early study demonstrating an association between levels of low-density lipoprotein
cholesterol and single-nucleotide polymorphisms (SNPs) within
HMGCR, a gene that produces the rate-limiting enzyme for
cholesterol synthesis.3 This enzyme is targeted for inhibition by
the statin class of drugs; however, it must be noted that this proof
of principle is retrospective, insofar as statins were developed on
the basis of biological knowledge developed many years before

this association.4 Similarly, GWAS for rheumatoid arthritis has
yielded a genomewide signiﬁcant hit in IL6R, which is the target
for tocilizumab, a monoclonal antibody previously approved by
the Food and Drug Administration (FDA) for treatment of
rheumatoid arthritis.5 In this context, it is notable that one PGC–
SCZ locus included DRD2, encoding the dopamine D2 receptor
that is targeted by all effective antipsychotic medications.6 Thus, it
is reasonable to ask whether any of the other genes at schizophrenia GWAS loci may serve as a target for future development
of novel antipsychotic pharmaceuticals.
Given the large number of genes within loci implicated by the
PGC–SCZ results, one way to prioritize the search space is to
identify those genes which encode proteins that are known to be
druggable. On the basis of biochemical principles of solubility and
lipophilicity (the so-called ‘rule of ﬁve’,7) it was originally estimated
that as many as 15% of all genes in the human genome may
produce proteins that can be bound by orally bioavailable
compounds.8,9 Recent estimates, based on technical advances
and modiﬁcations of the rule of ﬁve, suggest that the potential for
druggability may extend to 47000 genes.10 In practice, however,
the process of validating these targets with compounds that are
able to transition from preclinical models to clinical trials remains
a major bottleneck in the process of drug development.11
Consequently, it has been suggested that more rapid utility from
GWAS results may be obtained by the identiﬁcation of drug/target
combinations that have already been validated by preclinical work
and have progressed to human clinical trials and/or FDA
approval.12
Our approach here is based on the notion that the repurposing
of approved drugs, or those already in trials for other indications,
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is the fastest route to clinic.13 Such drugs already have known
safety proﬁles and pharmacokinetic data, even if they have failed
in generating robust efﬁcacy signal for their original indication.14
This approach has been endorsed by recent initiatives of the
National Institutes of Health15 and the National Institute of Mental
Health16 and has been an increasing trend in industry as well.17
To date, a number of existing compounds have been examined
for possible repurposing in schizophrenia, including anti-inﬂammatory drugs, anti-epileptic drugs and several hormones,18 based
on pathophysiologic hypotheses with varying levels of empirical
support. With the publication of large-scale GWAS data for
schizophrenia, it is now timely to utilize this genomic understanding for purposes of drug repositioning.
In the present study, we comprehensively examined all genes at
PGC–SCZ GWAS loci against databases of drug targets. The most
complete recent survey identiﬁed 1030 unique genes (~5% of all
protein-coding genes in the genome) serving as targets of drugs
that are either approved or in registered clinical trials;19 this list
was compared with the PGC–SCZ list of potential schizophrenia
candidate genes to determine the degree of overlap. Then, we
characterized the available compound(s) for each druggable
candidate gene in terms of mechanism of action and original
indication. For this analysis, we supplemented the list of druggable
targets with additional sources of publicly available information
on registered drug trials and approvals.
MATERIALS AND METHODS
Candidate genes
Input for all analyses was derived from the results of the PGC–SCZ study;1 a
total of 341 protein-coding RefSeq genes as listed in supplementary table 3
of that publication were considered. Brieﬂy, association of ~ 9.5 million
genetic variants to schizophrenia was examined across 46 case–control
cohorts of European ancestry, 3 case–control cohorts of east Asian ancestry
and 3 cohorts of trios (two parents and one affected offspring) of European
ancestry. SNPs crossing a threshold Po10-6 in meta-analysis of these
discovery cohorts (comprising 483 000 subjects) were then tested in a
replication cohort of ~ 1500 cases and ~ 66 000 controls of primarily
Icelandic ancestry from deCODE. Results were then combined across
all ~ 150 000 subjects, resulting in 128 LD-independent SNPs meeting
standard criteria for genomewide signiﬁcance (P ⩽ 5 × 10-8). An associated
region was deﬁned by all SNPs in moderately high LD (r2 ⩾ 0.6) around
each of these 128 top GWAS hits; overlapping or neighboring (within
250 kb) regions were merged, resulting in 108 independent loci. All
protein-coding genes contained within these loci, or starting within 20 kb
of these loci, were considered as candidate genes for purposes of the
present study. In addition, for loci containing no genes, the nearest gene
within 500 kb was considered a candidate.

Identiﬁcation of drug targets
The primary source of conﬁrmed druggable targets was the curated list of
1030 genes recently published by Rask-Anderson et al.19 This list was
developed with publicly available resources including: the DrugBank20
database (http://www.drugbank.ca); the Drugs@FDA database (http://
www.accessdata.fda.gov/scripts/cder/drugsatfda/); and the Drugs in
Clinical Trials Database (http://www.centerwatch.com). As described by
Rask-Anderson et al.,19 considerable manual curation is required due to
lack of uniform nomenclature and data organization available from these
primary datasources. Of the 1030 druggable genes, 555 unique genes were
identiﬁed that serve as targets of approved pharmaceuticals, which they
refer to as ‘established targets.’ An additional 475 genes were targeted by
compounds in registered clinical trials, referred to as ‘novel targets.’ The
full list of 1030 drug targets represents 5.06% of all genes (based on the
GENCODE21 version 19, July 2013 freeze, which estimates the total number
of protein-coding genes in the human genome at 20,345).

Characterization of drug mechanism of action and indication
To characterize all possible approved and in-trial drugs, we supplemented
the list of Rask-Anderson et al.,19 which was based on an April 2013 data
freeze, with three additional sources of information: the proprietary
© 2015 Macmillan Publishers Limited
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CiteLine database (accessed 1 June 2014); the publicly available DrugBank
database20 (accessed 20 July 2014); and the Drug-Gene Interaction
database10 (accessed 20 July 2014). Gene products were only considered
to be true drug targets if direct binding had been demonstrated; indirect
effects of up- or down-regulation were not included.

RESULTS
Of the 341 genes on the PGC list, 27 (7.92%) are drug targets on
the Rask-Anderson list. As described in the methods, we
supplemented the listings from Rask-Anderson19 with updated
information from three additional databases, which increased the
number of validated drug targets to 40 (11.7% of all candidate
genes derived from the PGC–SCZ GWAS). In the absence of
mechanistic understanding of the role of GWAS-derived genetic
variants in schizophrenia pathophysiology, this relatively large
percentage provides preliminary ground for optimism that one or
more of these targets may yield an effective treatment.
Next, we sought to characterize drugs targeting genes derived
from the PGC–SCZ in terms of FDA status, mechanism of action
and primary indication, in order to identify their potential for
repurposing. As displayed in Table 1, half of these genes (n = 20)
encode proteins that are the targets of approved drugs (note that
some approvals are from Europe rather than the FDA). Given that
we do not know whether speciﬁc GWAS-derived variants have
upward or downward effects on gene function, it is notable that
several of these targets have both agonist and antagonist drugs
on the market or under investigation.
In the table, gene targets that are more likely to be relevant to
schizophrenia pathophysiology are listed above the thin line.
Likelihood of relevance is deﬁned by either of the following
characteristics: the gene is targeted by a drug with existing
neuropsychiatric indications; or it encodes a protein that is
constitutive of a neurotransmitter receptor, ion channel or ion
transporter. Also indicated in the table are genes that are sole
members of the LD block encompassing a PGC–SCZ GWAS hit (cf.
supplementary table 3 in the PGC–SCZ paper1). Such genes are
arguably more likely to be relevant to schizophrenia pathophysiology than other GWAS-nominated genes, given that many of
the signiﬁcant LD blocks in the PGC–SCZ paper contain multiple
genes (up to a maximum of 26 genes at a single locus).
In addition to DRD2, ﬁve genes are noteworthy insofar as they
are the sole genes within an LD block and are likely to be relevant
to neuropsychiatric pathophysiology: CACNA1C, CACNB2, CACNA1I,
GRIN2A and HCN1. These might be considered the ‘low-hanging
fruit’ that are worthy of the most intensive immediate efforts
for further research. Arguably, GRIA1 could be added to this
list, as it is the nearest gene to an intergenic signal in the
PGC–SCZ GWAS. Drugs targeting the protein products of these
genes will be considered in greater detail in the discussion
section below.
An additional 20 genes without approved indications, but which
are the target of drugs that are currently in registered clinical trials
appears in Table 2. (Note that NISCH appears in both Tables 1 and
2, with approved agonists and in-trial antagonists.) As in Table 1,
targets with neuropsychiatric relevance are listed above the thin
line, and genes that are lone members of a GWAS-derived LD
block are highlighted. Intriguingly, one gene in Table 2 that meets
both of these criteria is GRM3, encoding the metabotropic 3
glutamate receptor. Agonism at this receptor has been the focus
of an initially promising drug development effort,22 although
subsequent large-scale trials were not successful.23–25 An antagonist of GRM3 is also the subject of a phase 2 clinical trial for the
treatment of depression (NCT01457677). Two other genes
targeted by drugs in clinical trials, which are notable for relevance and likelihood, are ATP2A2 and PRKD1. As an adenoassociated virus-1-based gene therapy, mydicar (targeting
ATP2A2) may be unwieldy for testing in schizophrenia.26 Bryostatin
Molecular Psychiatry (2015), 820 – 826
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Table 1.

PGC-SCZ genes that produce proteins which are targets of compounds with approved indications

Gene

Mechanism

Current indications

CA14
CACNA1C/CACNB2a

Carbonic anhydrase inhibitor
L-type calcium channel antagonist
L-type calcium channel activator
T-type calcium channel antagonist
Muscarinic receptor antagonist
Nicotinic receptor partial agonist
Nicotinic receptor antagonist
Dopamine receptor antagonist
Dopamine receptor agonist
AMPA receptor antagonist
AMPA receptor agonist
NMDA receptor antagonist
Sodium channel antagonist
Imidazoline I1 receptor agonist
Potassium/chloride transporter inhibitor

Glaucoma, diuretic, epilepsy
Hypertension, angina, irritable bowel syndrome
Arrhythmia (Ibutilide)
Epilepsy
Gastrointestinal disease, incontinence
Smoking cessation
Hypertension, smoking cessation
Schizophrenia, bipolar disorder, nausea
Parkinson’s disease
Epilepsy, anesthesia
Cognitive enhancementb
Epilepsy, Alzheimer’s disease
Anginab
Hypertensionb
Diuretic (congestive heart failure)

17,20 lyase inhibitor
Dipeptidyl peptidase 4 inhibitor
Heparin/thrombin stimulant
TGF-β pro-protein convertase inhibitor
MAP kinase inhibitor
Prostacyclin synthase inhibitor
Prostacyclin synthase inducer
Complement factor 1 inhibitor

Prostate cancer
Type 2 diabetes
Hemorrhage, thrombosis
Idiopathic pulmonary ﬁbrosisb
Acute promyelocytic leukemia
Analgesia (non-steroidal anti-inﬂammatory)c
Hypertension
Hereditary angioedemab

CACNA1I
CHRM4
CHRNA3/CHRNB4a
DRD2
GRIA1
GRIN2A
HCN1
NISCH
SLC12A4
CYP17A1
DPP4
F2
FURIN
MAPK3
PTGIS
SERPING1

Abbreviations: MAP, mitogen-activated protein; NMDA, N-methyl-D-aspartate; TGF, transforming growth factor. Boldface represents genes that are sole
members of an LD block of a PGC-SCZ genonewide association study (GWAS) hit. Underline represents gene that is the closest gene (though outside the
linkage disequilibrium (LD) block) for a PGC-SCZ GWAS hit. aBoth genes encode component subunits of the same receptor/channel. bCompound(s) for this
indication approved in Europe but not US. cOwing to side effects, drug is no longer approved.

Table 2.

PGC-SCZ genes that produce proteins which are targets of compounds in clinical trials

Gene

Mechanism

Primary indications

APH1A
ATP2A2
GFRA3
GRM3

Gamma secretase inhibitor
Na+/K+ ATPase inhibition
Neurotrophic growth factor/RET receptor agonist
Metabotropic glutamate receptor 3 agonist
Metabotropic glutamate receptor 3 antagonist
Imidazoline I1 receptor antagonist
Serine/threonine protein kinase activator

Alzheimer’s disease
Heart failure
Neuropathic pain
Schizophrenia
Depression
Peripheral neuropathy
Alzheimer’s, cancers (multiple)

Inhibitor of Akt phosphorylation
Monoclonal antibody
Synthetic peptide G2 checkpoint abrogator
Antisense inhibitor of clusterin
Retinoic acid hydroxylase inhibitor
Inhibitor of dihydropyrimidine dehydrogenase
Transcription factor DNA-decoy (EGR1 inhibitor)
Epoxide hydrolase inhibitor
Synthetic peptide (chaperonin function)
Recombinant heat shock protein (chaperonin function)
Recombinant lecithin cholesterol acyltransferase
Transcytosis of the low-density lipoprotein receptor-related protein
(used to deliver taxane across blood-brain barrier)
MMP inhibitor (angiogenesis inhibitor)
Telomerase inhibitor
BAFF receptor radioligand
BAFF receptor monoclonal antibody

Cancers (multiple)
Immunosuppressant
Cancer (mesothelioma)
Cancer (lung, breast, prostate)
Acne, psoriasis
Cancer (solid)
Post-surgical pain
Hypertension, COPD
Type 1 diabetes
Systemic lupus erythematosus
Atherosclerosis
Cancer (brain)

NISCH
PRKD1
AKT3
CD14
CDC25C
CLU
CYP26B1
DPYD
EGR1
EPHX2
HSPD1
HSPE1
LCAT
LRP1
MMP16
SMG6
TNFRSF13C

Cancer (lung, breast)
Cancer (multiple)
Myeloma/lymphoma
Immunosuppressant

Abbreviations: BAFF, B cell-activating factor; COPD, chronic obstructive pulmonary disease. Boldface represents genes that are sole members of an linkage
disequilibrium (LD) block of a PGC-SCZ genomewide association study (GWAS) hit.

is a partial agonist at multiple protein kinase isoforms (including
protein kinase D, the product of PRKD1), which is being tested
for its antineoplastic properties.27 Notably, protein kinase D
modulates the E-cadherin/β-catenin pathway, which is critical for
Molecular Psychiatry (2015), 820 – 826

synaptic plasticity.28 Although a repurposing of bryostatin may
be premature, especially given limited understanding of its
pharmacokinetics, this represents a promising avenue for
further study.
© 2015 Macmillan Publishers Limited
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Table 3.

Results of schizophrenia clinical trials for targets listed in Tables 1 and 2

Gene

Drug

Mechanism

Mode

Results

CACNA1C/CACNB2

Verapamil
Verapamil
Nilvadipine
Nifedipine
Nifedipine
MK-8998
Xanomeline
Varenicline
Mecamylamine
Piracetam
CX-516
Various
Memantine

Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Antagonist
Agonist
Partial agonist
Antagonist
Allosteric+ve
Allosteric+ve
Agonist
Antagonist

Adjunctive
Adjunctive
Adjunctive
Adjunctive
Adjunctive
Monotherapy
Monotherapy
Adjunctive
Adjunctive
Adjunctive
Adjunctive
Adjunctive
Adjunctive

LY2140023

Agonist

Monotherapy

No effects on symptoms in chronic patients58
Improved positive Sx in acute patients59
Improved negative Sx/no change in positive Sx60
No effects on symptoms in chronic patients61
Improved cognition in patients with tardive dyskinesia62
Failed trial (active comparator did not separate from placebo)40
Improved positive and negative symptoms63
No effects observed in meta-analysis of 7 RCTs64
Cognitive deterioration;65 no effect on cognition66
Improved PANSS compared with haldol+placebo41
No effect on symptoms or cognition42
Mixed results; see review de Bartolomeis et al.41 and meta-analysis44
improved negative Sx;46 improved positive and negative Sx;47
no effect on any Sx48
Successful proof-of-concept trial;22 multiple unsuccessful large trials23–25

CACNA1I
CHRM4
CHRNA3/CHRNB4
GRIA1
GRIN2A
GRM3

Abbreviations: +ve, positive modulator; PANSS, Positive and Negative Syndrome Scale; RCT, randomized controlled trial; Sx, symptoms.

DISCUSSION
Despite the unparalleled success of GWAS as a method for rapidly
advancing knowledge,29 questions remain about the potential
clinical utility of GWAS ﬁndings.30 Given the perplexing diversity of
ﬁndings presented by the PGC–SCZ GWAS, it may seem reasonable to extend similar skepticism to the prospect of translating
these results to the clinic. However, our results demonstrate: (1)
that the PGC-SCZ results are enriched for validated targets of both
approved and registered pharmaceutical compounds; and (2) that
amongst these targets, there are several examples of ‘low-hanging
fruit’—genes that are plausibly connected to schizophrenia
pathophysiology, and are relatively likely to be inﬂuenced by
the SNPs identiﬁed by the PGC–SCZ GWAS. Of course, one of the
genes meeting criteria for ‘low-hanging fruit’ is DRD2, which is
already well known in the context of schizophrenia treatment. In
the paragraphs below, we will examine each of the other top
targets in further detail. In addition, in Table 3, we present a
summary of clinical trials in schizophrenia with agents that bind to
targets in Tables 1 and 2.
Multiple compounds that inhibit voltage-gated L-type calcium
channels (VLCC), for which CACNA1C and CACNB2 encode constituent proteins, have been approved for cardiovascular indications.31 A few VLCC antagonists have been examined in clinical
trials in schizophrenia with mixed results; however, these studies
have been small, often poorly controlled, and most commonly
involved verapamil, a P-glycoprotein substrate with relatively
poor central nervous system permeability.32 Results of placebocontrolled trials in schizophrenia are summarized in Table 3; in
each of these trials, VLCC antagonists were administered as
adjunctive medicaton alongside stable treatment with conventional antipsychotics. Given the converging evidence of two
independent GWAS hits targeting VLCC components, as well as
the central role of calcium channels in regulating neurotransmitter
release and neuronal gene transcription, revisiting this class of
agents (especially dihydropyridines such as nimodipine, nifedipine
and isradipine) should be a high priority for the ﬁeld. Although
there is active investigation of calcium channel blockers in bipolar
disorder,33 there is currently just one registered clinical trial of a
calcium channel blocker in schizophrenia, testing the role of
isradipine as a potential adjunctive treatment for cognitive
dysfunction (NCT01658150). At the same time, caution must be
exercised regarding unavoidable cardiovascular effects of calcium
channel blockers, given the predominance of CACNA1C VLCCs in
the periphery relative to the central nervous system.34
© 2015 Macmillan Publishers Limited

One recent study has suggested that the CACNA1C risk allele
downregulates expression of the gene,35 raising the possibility
that antipsychotic effect might require calcium channel activation,
rather than inhibition. Ibutilide, a compound approved for atrial
ﬁbrillation, is thought to act via calcium channel activation, insofar
as it is blocked in vitro by nifedipine.36 However, its relative activity
at the VLCC in vivo is controversial.37 Determination of the
direction of allelic effects at CACNA1C is an urgent priority; in
contrast to the post-mortem gene expression study mentioned
immediately above,35 a recent investigation of induced neurons
derived from human ﬁbroblasts of subjects with varying CACNA1C
genotypes reported that the risk allele results in higher levels of
gene expression.38
An argument for urgency can also be made for the T-type
calcium channel (CACNA1I), which is targeted by the FDAapproved anticonvulsant zonisamide. Unfortunately, zonisamide
has been found to have potential psychotogenic and other
deleterious cognitive and psychiatric effects,39 suggesting the
possibility that agonism of T-type channels may be a more
advantageous approach. However, to our knowledge, no activators of this channel are approved or are in clinical trials. A novel
T-type calcium channel antagonist, MK-8998, was the subject of a
recently reported failed trial, in which the active comparator
(olanzapine) did not separate from placebo.40 Given that no
conclusions can be drawn from such a trial, additional testing of
this compound is warranted.
The potential association of schizophrenia with variants at
GRIN2A (encoding an N-methyl-D-aspartate (NMDA) receptor
subunit) is consistent with the ﬁeld’s longstanding interest in
the psychotomimetic properties of NMDA antagonists. Direct and
indirect NMDA agonists have been widely studied as potential
adjunctive treatments, primarily to ameliorate cognitive deﬁcits
and negative symptoms (for example, avolition, alogia and
affective ﬂattening) associated with schizophrenia, with mixed
results (see review de Bartolomeis et al.41). Curiously, large multicenter
controlled trials42,43 have been generally negative for NMDA
glycine-site agonists such as glycine, D-serine and D-cycloserine,
yet meta-analyses have indicated statistically signiﬁcant effects of
the class as a whole, especially sarcosine.44 Initial promising results
for the novel glycine transport inhibitor, bitopertin45 have not
been replicated in large-scale phase III trials. It is possible that this
conﬂicting pattern of results may be indicative of subgroups of
patients, perhaps genetically deﬁned, with varying response
to NMDA agents. However, this speculative pharmacogenetic
Molecular Psychiatry (2015), 820 – 826
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hypothesis would require rigorous comparison of patients with
and without the PGC–SCZ GRIN2A risk allele.
Counterintuitively, the NMDA antagonist memantine (approved
for use in Alzheimer’s) may have therapeutic properties at low
doses due to its rapid off-set of binding and voltage dependence.
Clinical trials in schizophrenia have demonstrated mixed results,
with some evidence of improvement of negative symptoms.46–48
Glutamate transmission is also implicated by the potential
association with GRIA1, which encodes a subunit of the α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid-type ionotropic
glutamate receptor. It has been demonstrated that this receptor
is critical to short-term habituation, which is deﬁcient in gria1
knockout mice; these knockouts demonstrate a form of aberrant
salience proposed as a model for delusional symptomatology in
schizophrenia.49 Consequently, allosteric modulators that serve
to activate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors, including ampakines and members of the racetam
family, may have potential for the treatment of schizophrenia. One
small study conducted in Iran has provided preliminary evidence
for greater reduction of Positive and Negative Syndrome Scale
scores in patients treated with piracetam in combination with
haloperidol, compared with haloperidol plus placebo.50 However,
another study failed to show any efﬁcacy for a novel ampakine
(CX516) as an adjunctive agent for either cognitive deﬁcits or
clinical symptoms of schizophrenia.51 Notably, aniracetam is
approved in Europe for the treatment of cognitive deﬁcits
associated with Alzheimer’s disorder.
HCN1 encodes a voltage-gated potassium/sodium channel,
strongly expressed in the dendrites of cortical and hippocampal
pyramidal cells.52 This channel has been implicated as a pacemaker
regulating working memory function, making it an attractive target
for schizophrenia treatment.53 However, the HCN1 antagonist
ivabradine, approved in Europe for angina, does not cross the
blood–brain barrier. Nevertheless, the genetic association should
serve to bolster research on existing agents that may have indirect
effects on HCN1 activity, including lamotragine and gabapentin.
This brief survey only touches on the most promising
candidates in Table 1, as deﬁned by statistical speciﬁcity of
PGC–SCZ GWAS results and biological properties of the targets.
We encourage follow-up genetic and biological research for each
of the 40 listed targets; for example, Table 3 demonstrates that
other neurotransmitter receptors, including both muscarinic and
nicotinic cholinergic subtypes implicated at complex (multigenic)
PGC–SCZ GWAS loci, have been targets of novel treatment
development in schizophrenia. (In this context, it is noteworthy
that clozapine and olanzapine also demonstrate binding at the M4
muscarinic receptor,54 and preclinical research on more selective
M4 agents is well advanced.55) Initial research necessarily must be
focused on deﬁnitively establishing that the statistical GWAS
signal functionally implicates the speciﬁed gene of interest, and
in which direction (up- or down-regulation) the risk allele functions. The absence of this information is the greatest limitation
in our ability to translate GWAS hits into clinical targets. In this
regard, data emerging from the new NIMH-funded PsychENCODE
project (RFA-MH-14-020), designed to identify non-coding functional genomic elements in brain tissue, may be especially useful.
It is also important to note that our survey is limited to direct
effects on targeted genes; future pathway analyses may greatly
enhance our ability to exploit the results of GWAS for purposes of
target identiﬁcation. A key example of the utility of such an
approach is provided by a recent large-scale GWAS meta-analysis
in rheumatoid arthritis, which was able to use protein–protein
interaction networks to retrospectively link GWAS hits with a wide
variety of existing treatments.56 Unfortunately, preliminary pathway analysis conducted by the PGC was unable to identify
signiﬁcantly enriched biological pathways.1 Moreover, prospective
use of interactome analysis presents the challenge of exponentially increasing potential targets.
Molecular Psychiatry (2015), 820 – 826

It has been argued that the utility of GWAS is limited by the
small effect size of GWAS-identiﬁed genetic variants on disease
phenotypes. Although small effect sizes do mitigate the utility of
GWAS for clinical diagnostic purposes, the size of the detected
effects does not invalidate GWAS as a tool for identiﬁcation of
relevant biological insights.2 For example, D2 antagonists are
powerful antipsychotic agents, despite the fact that the risk allele
at the PGC–SCZ locus containing DRD2 conveys an odds ratio of
only 1.08, and is ranked 35th on the list of GWAS hits in order of
statistical strength of association. Similarly, the efﬁcacy of statins
in reducing cholesterol is not proportional to the effect size on
cholesterol levels of the HMGCR variant identiﬁed by GWAS.3,12
A large-scale review recently demonstrated that each copy of the
G allele at the HMGCR variant rs17238484 is associated with a
mean 0.06 mmol l-1 lower value of low-density lipoprotein cholesterol, whereas statin treatment results in a mean low-density
lipoprotein reduction of 0.92 mmol l-1.57 In this context, genetic
variation and pharmacologic manipulation can be seen as two
separate mechanisms for altering the same biological target.
The complexity of the PGC–SCZ results still reminds us that
schizophrenia is a highly heterogeneous disorder, and it is unlikely
that any single-treatment target or strategy will be efﬁcacious
across all, or even the majority, of patients. The mixed results of
studies already conducted for these targets, as listed in Table 3,
suggest that expected outcomes may be subtle or variable across
different samples. Therefore, GWAS-nominated genetic variants
should be utilized in clinical research as potential pharmacogenetic moderators of treatment response, in studies of established dopaminergic agents as well as any novel or repurposed
compounds.
With these limitations in mind, intensive research into the
above-listed targets represents a potential fast track toward novel
treatments for schizophrenia. Existing compounds, as listed in
Tables 1, 2, 3, overcome a series of obstacles that currently
hamper psychiatric drug development: (1) the lengthy time
necessary for the drug development process (a dozen years or
more from target identiﬁcation to clinical validation); (2) the lack
of access to affected tissue to test target engagement; (3) the
limitations of animal models of psychiatric disease; and (4) the
retreat of investment in psychopharmacology by the pharmaceutical industry.13
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